Compare Dishman Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs DR. REDDYS LAB - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA DR. REDDYS LAB DISHMAN PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 25.1 40.4 62.2% View Chart
P/BV x 3.3 5.5 60.6% View Chart
Dividend Yield % 0.7 0.5 138.2%  

Financials

 DISHMAN PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
DR. REDDYS LAB
Mar-20
DISHMAN PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs3743,363 11.1%   
Low Rs1292,352 5.5%   
Sales per share (Unadj.) Rs197.81,054.2 18.8%  
Earnings per share (Unadj.) Rs21.2121.9 17.4%  
Cash flow per share (Unadj.) Rs34.7190.2 18.3%  
Dividends per share (Unadj.) Rs2.0025.00 8.0%  
Dividend yield (eoy) %0.80.9 90.8%  
Book value per share (Unadj.) Rs179.9938.7 19.2%  
Shares outstanding (eoy) m80.69166.17 48.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.7 46.9%   
Avg P/E ratio x11.923.4 50.6%  
P/CF ratio (eoy) x7.215.0 48.2%  
Price / Book Value ratio x1.43.0 46.0%  
Dividend payout %9.420.5 46.0%   
Avg Mkt Cap Rs m20,306474,831 4.3%   
No. of employees `0000.821.7 3.8%   
Total wages/salary Rs m5,35533,802 15.8%   
Avg. sales/employee Rs Th19,252.78,091.0 238.0%   
Avg. wages/employee Rs Th6,459.51,561.3 413.7%   
Avg. net profit/employee Rs Th2,064.1935.8 220.6%   
INCOME DATA
Net Sales Rs m15,961175,170 9.1%  
Other income Rs m2656,206 4.3%   
Total revenues Rs m16,226181,376 8.9%   
Gross profit Rs m4,10324,421 16.8%  
Depreciation Rs m1,09111,348 9.6%   
Interest Rs m944983 96.1%   
Profit before tax Rs m2,33418,296 12.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m1561 0.2%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624-1,403 -44.4%   
Profit after tax Rs m1,71120,260 8.4%  
Gross profit margin %25.713.9 184.4%  
Effective tax rate %26.7-7.7 -348.5%   
Net profit margin %10.711.6 92.7%  
BALANCE SHEET DATA
Current assets Rs m11,018125,991 8.7%   
Current liabilities Rs m9,51772,141 13.2%   
Net working cap to sales %9.430.7 30.6%  
Current ratio x1.21.7 66.3%  
Inventory Days Days11073 151.2%  
Debtors Days Days35105 33.3%  
Net fixed assets Rs m16,30483,854 19.4%   
Share capital Rs m161831 19.4%   
"Free" reserves Rs m12,907155,157 8.3%   
Net worth Rs m14,516155,988 9.3%   
Long term debt Rs m4,1891,304 321.3%   
Total assets Rs m29,805232,253 12.8%  
Interest coverage x3.519.6 17.7%   
Debt to equity ratio x0.30 3,452.5%  
Sales to assets ratio x0.50.8 71.0%   
Return on assets %8.99.1 97.4%  
Return on equity %11.813.0 90.8%  
Return on capital %17.512.6 139.0%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95284,193 5.9%   
Fx outflow Rs m69739,616 1.8%   
Net fx Rs m4,25544,577 9.5%   
CASH FLOW
From Operations Rs m2,78629,841 9.3%  
From Investments Rs m-1,529-4,923 31.1%  
From Financial Activity Rs m-941-25,159 3.7%  
Net Cashflow Rs m316-266 -118.9%  

Share Holding

Indian Promoters % 61.4 25.5 240.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 5.4 68.5%  
FIIs % 12.7 35.3 36.0%  
ADR/GDR % 0.0 18.5 -  
Free float % 22.1 15.3 144.4%  
Shareholders   46,261 75,885 61.0%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare DISHMAN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; JSW Steel and ICICI Bank Among Top Nifty Gainers(Closing)

Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.

Related Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS